Alembic Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5vlrmvda9b2kk6016r584c7c.pdf

Key Takeaways


India Branded Business: Stabilization, Not Acceleration

G. Krishnan: "I would like to, actually, you know, if you look at the, from purely from a modeling perspective, if you look at the growth for the second half of the financial year, you should consider the fact that the last year's second half was a higher base."

US Generics: Volume Offsets Price, But Entresto Disappoints

Pranav Amin: "That's been picked up. Well, there was a lot of competition on that product, and pricing was much lower than what I would have liked or would have expected."

Pivya & the Branded US Pivot

Pranav Amin: "I believe this can be a good de-risk from the generic business and the pricing challenges that we have in the generic business. And we can build a good franchise in women's health. And that's something that we're going to aim to do."

R&D and Pipeline: Peptides and Complex Injectables

Pranav Amin: "To be honest, I don't think we will ever go back to the 12%-13%-14% kind of R&D spends that we were doing when margins and the returns in the US are much higher than what they are right now."

International Generics and API


Margins, Debt and the Path to 20% EBITDA


Guidance & Commitments

CommitmentSpecificsTimeline
R&D spend₹600-650 crores full-year (~8% of revenue)FY26
US product launches4-5 products in Q3, 4-5 in Q4FY26
Pivya US launchBegin late Q4; Q1 FY27 first full quarterLate Q4 FY26
ROW generics growth15-20% full-year (vs 30% in Q2)FY26
EBITDA marginImprove to 18-19%, then 20%Next couple of years
Net debt reductionGradual reduction ex-Pivya investmentFY27
India business catch-upRepresented market growth to match IPM growthSoon (no date)
Complex injectable approvalsSome approvals expected; limited competitionNext couple of months

Key Metrics

MetricQ2 FY26
Revenue (half-yearly)₹3,621 cr, +13% YoY
India Branded Business revenue₹639 cr, +5% YoY
US business growth+21%, supported by higher volumes
Rest of world markets growth+31%, exceptional due to low base in H1 last year
API business growth+15%
EBITDA before R&D (half-yearly)₹927 cr, margin 26%, +28% YoY
EBITDA post R&D (half-yearly)₹613 cr, ~17% of revenue
R&D expenses₹187 cr, +41% YoY; ~10% of revenue
Profit before tax (before exceptional items)₹225 cr, +34% YoY
Profit after tax (before exceptional items)₹185 cr, +30% YoY
Profit after tax adjusted for insurance claim+20% YoY
Net debt₹1,280 cr as of 30 Sep, vs ₹967 cr in Jun '25
Net working capital₹2,921 cr vs ₹2,734 cr as of Mar '25
Interest cost₹76 cr, up from ₹71 cr in Q1
ANDAs filed during quarter2, cumulative filings at 269
ANDA approvals received6 approvals and 1 tentative approval
Products launched in US3
Cumulative ANDA approvals226 including 21 tentative approvals
Expected US launches4-5 in Q3 and 4-5 in Q4 FY26
Full-year R&D guidance₹600-650 cr, maintained
ROW generics expected full-year growth15-20%
API expected full-year growth~10%
US gross margin guidance70-75% range reiterated
R&D spend going forward~8% of revenue